Previous Close | 0.9000 |
Open | 0.9000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 12.50 |
Expire Date | 2026-01-16 |
Day's Range | 0.9000 - 0.9000 |
Contract Range | N/A |
Volume | |
Open Interest | 245 |
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against re-election of three directors on the board of the COVID-19 vaccine maker. Shah Capital, which currently owns a nearly 7.5% stake in Novavax, said it intends to vote against directors Richard Douglas, Margaret McGlynn and David Mott at the company's upcoming shareholder meeting in June. "We believe that fresh perspectives are desperately needed in the boardroom to steer Novavax towards sustainable profitable growth," the hedge fund said in a statement.
Highlights Novavax’s Massive Untapped Value That it Believes is Being Hindered by an Overly Conservative Board and Management That Clings to Failed Strategies and Have Undermined Stockholder Value Calls for Fresh Perspectives in the Boardroom to Restore Investor Confidence in the Company Files Preliminary Proxy and Urges Stockholders to Vote AGAINST The Re-Election of all Class II Directors and AGAINST The Approval of Three of the Company’s Other Proposals at the Annual Meeting RALEIGH, N.C., Ma
In the latest trading session, Novavax (NVAX) closed at $4.33, marking a +0.93% move from the previous day.